{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:47:59Z","timestamp":1776494879770,"version":"3.51.2"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.semarthrit.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T04:40:32Z","timestamp":1529469632000},"page":"658-668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Combination urate-lowering therapy in the treatment of gout: What is the evidence?"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-1894","authenticated-orcid":false,"given":"Fernando","family":"Perez-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.06.004_bib0001","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","article-title":"Epidemiology of gout","volume":"12","author":"Roddy","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0002","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/annrheumdis-2013-204647","article-title":"The global burden of gout: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"Smith","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0003","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0004","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/art.27356","article-title":"Cellular characterization of the gouty tophus: a quantitative analysis","volume":"62","author":"Dalbeth","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7326\/0003-4819-54-3-452","article-title":"Identification of urate crystals in gouty synovial fluid","volume":"54","author":"McCarty","year":"1961","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0006","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","article-title":"The british society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0009","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","article-title":"Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative","volume":"73","author":"Sivera","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0010","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0011","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0012","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0013","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0014","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/annrheumdis-2015-eular.1188","article-title":"Relationship between sustained lowering of serum urate levels and improvements in gout flares and tophus area: pooled exploratory analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitor combination therapy","volume":"74","author":"Terkeltaub","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0016","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrrheum.2014.32","article-title":"Optimizing current treatment of gout","volume":"10","author":"Rees","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0017","first-page":"35","article-title":"Pharmacology of drugs for hyperuricemia. mechanisms, kinetics and interactions","volume":"147","author":"Pea","year":"2005","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/ard.39.5.417","article-title":"Renal impairment and gout","volume":"39","author":"Gibson","year":"1980","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0019","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jbspin.2016.04.007","article-title":"Patients with gout differ from healthy subjects in renal response to changes in serum uric acid","volume":"84","author":"Liu","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","article-title":"Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney","volume":"18","author":"Miner","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0021","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0022","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0023","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0024","first-page":"983","article-title":"Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis","volume":"20","author":"Borghi","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0025","doi-asserted-by":"crossref","unstructured":"Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev 2014:CD010457.","DOI":"10.1002\/14651858.CD010457.pub2"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0026","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1440-1797.2010.01368.x","article-title":"Interactions of urate transporter URAT1 in human kidney with uricosuric drugs","volume":"16","author":"Shin","year":"2011","journal-title":"Nephrology"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0027","doi-asserted-by":"crossref","first-page":"34995","DOI":"10.1038\/srep34995","article-title":"Mechanism of high affinity inhibition of the human urate transporter URAT1","volume":"6","author":"Tan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0028","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0029","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/molbev\/msw116","article-title":"Coevolution of URAT1 and uricase during primate evolution: implications for serum urate homeostasis and gout","volume":"33","author":"Tan","year":"2016","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by organic anion transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0031","first-page":"897","article-title":"A systematic review of uric acid transporter 1 (URAT 1) inhibitors for the treatment of hyperuricemia and gout and an insight into the structure-activity relationship (SAR)","volume":"36","author":"Cai","year":"2017","journal-title":"Chinese J Struct Chem"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0032","first-page":"151","article-title":"Urate crystal deposition disease and gout-new therapies for an old problem","volume":"49","author":"Girardet","year":"2014","journal-title":"Annu Rep Med Chem"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0033","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41598-017-00706-7","article-title":"Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0034","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0035","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0036","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0037","article-title":"Examination of serum uric acid (sUA) lowering and safety with extended lesinurad\u202f+\u202fallopurinol treatment in subjects with gout [abstract]","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0038","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000584","article-title":"Pharmacodynamic effects and safety of verinurad in combination with febuxostat versus febuxostat alone in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000584","article-title":"Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0041","doi-asserted-by":"crossref","unstructured":"Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, et al. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford). 2018 Jun 1. doi: 10.1093\/rheumatology\/key100. [Epub ahead of print]. PM:29868853.","DOI":"10.1093\/rheumatology\/key100"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0042","first-page":"S1014","article-title":"Arhalofenate, a potential novel treatment for hyperuricemia, with or without metabolic co-morbidities, in patients with gout: meta-analysis of urate lowering in four phase 2 studies in type 2 diabetes [abstract]","volume":"63","author":"Saha","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0043","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3899\/jrheum.161062","article-title":"The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout","volume":"44","author":"Steinberg","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0044","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0046","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0047","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/art.1780090306","article-title":"Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout","volume":"9","author":"Goldfarb","year":"1966","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0048","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/ard.25.Suppl_6.634","article-title":"Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone","volume":"25","author":"Kuzell","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0049","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0002-9343(64)90131-7","article-title":"Effect of allopurinol (4-hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout","volume":"37","author":"Y\u00fc","year":"1964","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2169\/internalmedicine.53.0698","article-title":"Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure","volume":"53","author":"Maekawa","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0051","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","article-title":"An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition","volume":"278","author":"Okamoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0052","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0053","first-page":"1212","article-title":"Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study","volume":"97","author":"Arntz","year":"1979","journal-title":"Fortschr Med"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0054","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/263720","article-title":"Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients","volume":"2014","author":"Azevedo","year":"2014","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0055","first-page":"719","article-title":"Effectiveness and tolerance of long-term uricosuric treatment","volume":"45","author":"Berg","year":"1990","journal-title":"Z Gesamte Inn Med"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0056","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/BF01712184","article-title":"Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?","volume":"62","author":"Mertz","year":"1984","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0057","first-page":"506","article-title":"Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol","volume":"50","author":"Ohno","year":"2008","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0058","first-page":"1087","article-title":"The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia","volume":"87","author":"Akkasilpa","year":"2004","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0059","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00315283","article-title":"The effect of benzbromarone on allopurinol\/oxypurinol kinetics in patients with gout","volume":"44","author":"Muller","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/hr.2016.139","article-title":"Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia","volume":"40","author":"Ohta","year":"2017","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0061","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3899\/jrheum.121301","article-title":"Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population","volume":"40","author":"Pui","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0062","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects","volume":"47","author":"Stocker","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0063","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0064","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients","volume":"26","author":"Reinders","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222845","article-title":"Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease","author":"Case","year":"2018","journal-title":"BMJ Case Rep 2018"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0066","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0067","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.2215\/CJN.01760213","article-title":"Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones","volume":"8","author":"Goldfarb","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0068","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","article-title":"Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia","volume":"53","author":"Fleischmann","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0069","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0070","article-title":"Clinical response of tophus and flares to extended use of lesinurad in combination with a xanthine oxidase inhibitor in patients with gout [abstract]","volume":"68","author":"Bardin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0071","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1119","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of concomitant multiple dose administration of verinurad (RDEA3170) and allopurinol in adult male subjects with gout","author":"Kankam","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0072","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0073","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12325-011-0096-z","article-title":"Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance","volume":"29","author":"Benford","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0074","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0075","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1185\/03007995.2012.684045","article-title":"Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis","volume":"28","author":"Han","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0076","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1185\/03007995.2011.570745","article-title":"A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes","volume":"27","author":"Hutchins","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0077","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1185\/03007990802262457","article-title":"Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients","volume":"24","author":"Neutel","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0078","doi-asserted-by":"crossref","first-page":"g3318","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0079","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.curtheres.2017.01.005","article-title":"Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review","volume":"84","author":"Vijayakumar","year":"2017","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.semarthrit.2018.06.004_bib0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1759720X16646703","article-title":"Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications","volume":"8","author":"Sattui","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218301653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218301653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:23:19Z","timestamp":1551205399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218301653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0049017218301653"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.06.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination urate-lowering therapy in the treatment of gout: What is the evidence?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}